Intraocular Pressure-Lowering Efficacy and Safety of Fermented Cordyceps cicadae Mycelia

2021 ◽  
Vol 10 (01) ◽  
pp. 33-39
Author(s):  
瑞霞 徐
Keyword(s):  
Intraocular Pressure ◽  
Efficacy And Safety ◽  
Pressure Lowering ◽  
Cordyceps Cicadae

scholarly journals Prevention of intraocular pressure elevation after argon laser trabeculoplasty in primary open angle glaucoma

2011 ◽  
Vol 139 (1-2) ◽  
pp. 12-17
Author(s):  
Marija Bozic ◽  
Paraskeva Hentova-Sencanic ◽  
Djordje Kontic ◽  
Vujica Markovic ◽  
Ivan Marjanovic
Keyword(s):  
Intraocular Pressure ◽  
Open Angle Glaucoma ◽  
Argon Laser ◽  
Similar Efficacy ◽  
Efficacy And Safety ◽  
Argon Laser Trabeculoplasty ◽  
Pressure Elevation ◽  
Laser Trabeculoplasty ◽  
Intraocular Pressure Elevation ◽  
Pressure Lowering

Introduction. Argon laser trabeculoplasty (ALT) is an intraocular pressure lowering method that is overall safe and powerful, but often complicated by transient postoperative intraocular pressure rises. In prevention of this complication, we frequently use two potent alpha-adrenergic agonists - brimonidine and apraclonidine. Objective. The aim of this study was to compare brimonidine 0.2% and apraclonidine 0.5% efficacy and safety in prevention of intraocular pressure elevation after ALT. Methods. This was a prospective, randomized, double-masked and comparative study. This study included 27 POAG patients, 15 received 0.2% brimonidine, and 12 received 0.5% apraclonidine before laser surgery (22 eyes in both groups). Intraocular pressure readings were taken 1, 2, 3, 24 hours and 7 days after ALT. Student?s t-test was used to analyze data between two groups, and ?2 test to compare data within groups. Value p less than 0.05 was considered statistically significant. Results. We found statistically significantly lower IOP in eyes that received 0.2% brimonidine at readings taken 1 hour after ALT (p=0.001). There were no statistically significant differences in other IOP readings between two groups. Conclusion. A single preoperative drop of brimonidine 0.2% had similar efficacy and safety as apraclonidine 0.5% in preventing transient IOP elevations after ALT.

Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4

2008 ◽  
Vol 92 (10) ◽  
pp. 1387-1392 ◽  
Author(s):  
R D Williams ◽  
J S Cohen ◽  
R L Gross ◽  
C-c Liu ◽  
E Safyan ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Ocular Hypertension ◽  
Efficacy And Safety ◽  
Term Efficacy ◽  
Pressure Lowering

scholarly journals Intraocular pressure-lowering effect of Cordyceps cicadae mycelia extract in a glaucoma rat model

2021 ◽  
Vol 18 (4) ◽  
pp. 1007-1014
Author(s):  
Chi-Ting Horng ◽  
Ya-Lan Yang ◽  
Chin-Chu Chen ◽  
Yu-Syuan Huang ◽  
Chun Chen ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Rat Model ◽  
Lowering Effect ◽  
Pressure Lowering ◽  
Cordyceps Cicadae

Efficacy and safety of the ab interno gelatin stent in severe pseudoexfoliation glaucoma compared to non-pseudoexfoliation glaucoma at 6 months

2019 ◽  
Vol 30 (5) ◽  
pp. 1028-1033 ◽  
Author(s):  
Nimrod Dar ◽  
Tal Sharon ◽  
Idan Hecht ◽  
Maya Kalev-Landoy ◽  
Zvia Burgansky-Eliash
Keyword(s):  
Intraocular Pressure ◽  
Patient Characteristics ◽  
Similar Efficacy ◽  
Efficacy And Safety ◽  
Pseudoexfoliation Glaucoma ◽  
Pressure Lowering ◽  
Surgery Rates ◽  
Glaucoma Group ◽  
Ab Interno

Purpose: To compare the efficacy and safety of the XEN45 Gel Stent surgery between patients with and without severe pseudoexfoliation glaucoma. Methods: In this retrospective, single-center, comparative chart review, records of 24 eyes of 23 patients with pseudoexfoliation glaucoma and 24 eyes of 23 patients with non-pseudoexfoliation glaucoma with severe glaucoma, defined as uncontrolled intraocular pressure on maximally tolerated medical therapy, were reviewed. All patients were treated with XEN45 Gel Stent surgery, in either a standalone procedure (84.8%) or combined with phacoemulsification (15.2%). Mean intraocular pressure, mean number of intraocular pressure-lowering medications, change in best-corrected visual acuity and needling or rescue surgery rates were assessed. Success was defined as at least 20% decrease in baseline intraocular pressure among treatment-free patients. Results: Patient characteristics were similar between the groups. At 6 months, intraocular pressure in the pseudoexfoliation glaucoma group decreased by 32% (24.3 ± 9 mmHg–14.8 ± 7 mmHg, p < 0.001), with comparable decrease in intraocular pressure in the non-pseudoexfoliation glaucoma group (22.6 ± 7 mmHg–16.7 ± 6 mmHg, p = 0.011). Similar rates of patients required topical anti-glaucoma therapy (29% vs 22%, p = 0.559), needling (54% vs 37%, p = 0.247), and rescue trabeculectomy (13% in both, p = 1.00) at the last follow-up. However, intraocular pressure decreased more in the pseudoexfoliation glaucoma group among treatment-free patients (–10.1 ± 8.0 mmHg vs −4.1 ± 8.1 mmHg, p = 0.043), and final intraocular pressure was lower in the pseudoexfoliation glaucoma group (12.2 ± 3.5 mmHg vs 15.8 ± 5.7 mmHg, p = 0.044). Conclusions: The XEN45 Gel Stent implant demonstrated similar efficacy and safety among severe pseudoexfoliation glaucoma and non-pseudoexfoliation glaucoma patients. Greater magnitude of decreased intraocular pressure occurred among treatment-free pseudoexfoliation glaucoma patients.

Sign in / Sign up

Export Citation Format

Share Document